Fatty liver disease is a major untapped opportunity for nutraceuticals; platform established
Research, focus and regulatory cunning will be needed if the nutraceutical industry is to tap into the relatively unexplored area of non-alcoholic fatty liver disease (NAFLD), says the consultancy firm behind a new dedicated clinical trial platform.